Gadoterate meglumine - Guerbet

Drug Profile

Gadoterate meglumine - Guerbet

Alternative Names: DOTA-gadolinium meglumine; DOTA-Gd meglumine; Dotarem; Gadolinium-DOTA meglumine; Gd-DOTA meglumine

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Guerbet
  • Class Gadolinium-containing contrast agents; Heterocyclic compounds; Hexosamines; Macrocyclic compounds; Organometallic compounds; Sugar alcohols
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed CNS disorders; Vascular disorders

Most Recent Events

  • 05 Sep 2017 Registered for CNS disorders (Diagnosis, In infants, In neonates) in USA (IV)
  • 05 Sep 2017 Adverse events data from a phase IV trial in CNS disorders (Diagnosis) released by Guerbet
  • 21 Mar 2013 Registered for CNS disorders (diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top